Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, Karlan BY (2021) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:77–102. https://doi.org/10.6004/jnccn.2021.0001

Article  CAS  PubMed  Google Scholar 

Guha T, Malkin D (2017) Inherited TP53 mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect Med 7:a026187. https://doi.org/10.1101/cshperspect.a026187

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA (2021) Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol 22:1787–1798. https://doi.org/10.1016/S1470-2045(21)00580-5

Article  PubMed  PubMed Central  Google Scholar 

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 135:584–590. https://doi.org/10.1097/CM9.0000000000002108

Article  PubMed  Google Scholar 

Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB (2020) Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer 122:405–412. https://doi.org/10.1038/s41416-019-0654-8

Article  CAS  PubMed  Google Scholar 

McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11:607–613. https://doi.org/10.1007/s10689-012-9557-z

Article  CAS  PubMed  Google Scholar 

Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugières L, Caron O, Benusiglio PR, Bressac-de Paillerets B, Bonadona V, Bonaïti-Pellié C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33:2345–2352. https://doi.org/10.1200/JCO.2014.59.5728

Article  CAS  PubMed  Google Scholar 

Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y (2020) Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. Int J Cancer 146:487–495. https://doi.org/10.1002/ijc.32424

Article  CAS  PubMed  Google Scholar 

Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, Bateman AC, Jones L, Haywood L, Evans DG, Birch JM, Alsalmi OA, Henderson A, Poplawski N, Eccles DM (2019) Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). J Pathol Clin Res 5:189–198. https://doi.org/10.1002/cjp2.133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, Speare V, Dolinsky JS, Chao EC, Garber JE (2018) Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. J Natl Cancer Inst 110:863–870. https://doi.org/10.1093/jnci/djy001

Article  PubMed  Google Scholar 

Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S (2017) NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw 15:9–20. https://doi.org/10.6004/jnccn.2017.0003

Article  CAS  PubMed  Google Scholar 

Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D (2020) Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. J Clin Oncol 38:2080–2106. https://doi.org/10.1200/JCO.20.00299

Article  CAS  PubMed  Google Scholar 

Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, Mathieu MC, Marsiglia H, Bourgier C (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104. https://doi.org/10.1186/1748-717X-5-104

Article  PubMed  PubMed Central  Google Scholar 

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241. https://doi.org/10.1056/NEJMoa022152

Article  PubMed  Google Scholar 

Guan Y, Hu H, Peng Y, Gong Y, Yi Y, Shao L, Liu T, Li G, Wang R, Dai P, Bignon YJ, Xiao Z, Yang L, Mu F, Xiao L, Xie Z, Yan W, Xu N, Zhou D, Yi X (2015) Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer 14:9–18. https://doi.org/10.1007/s10689-014-9749-9

Article  PubMed  Google Scholar 

Huang X, Cai XY, Liu JQ, Hao WW, Zhou YD, Wang X, Xu Y, Chen C, Lin Y, Wang CJ, Song Y, Sun Q (2020) Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population. Gland Surg 9:775–787. https://doi.org/10.21037/gs-20-531

Article  PubMed  PubMed Central  Google Scholar 

Sun S, Liu Y, Eisfeld AK, Zhen F, Jin S, Gao W, Yu T, Chen L, Wang W, Chen W, Yuan M, Chen R, He K, Guo R (2019) Identification of germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing: a retrospective study. Front Oncol 9:550. https://doi.org/10.3389/fonc.2019.00550

Article  PubMed  PubMed Central  Google Scholar 

Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC, Attardi LD, Crowley S, Evans DG, Feng BJ, Foreman AKM, Frone MN, Huether R, James PA, McGoldrick K, Mester J, Seifert BA, Slavin TP, Witkowski L, Zhang L, Plon SE, Spurdle AB, Savage SA, ClinGen TP53 Variant Curation Expert Panel (2021) Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat 42:223–236. https://doi.org/10.1002/humu.24152

Article  CAS  PubMed  Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30

Article  PubMed  PubMed Central  Google Scholar 

Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q (2020) Genomic profiling comparison of germline BRCA and non-BRCA carriers reveals CCNE1 amplification as a risk factor for non-BRCA carriers in patients with triple-negative breast cancer. Front Oncol 10:583314. https://doi.org/10.3389/fonc.2020.583314

Article  PubMed  PubMed Central  Google Scholar 

Braxton DR, Zhang R, Morrissette JD, Loaiza-Bonilla A, Furth EE (2016) Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. Int J Cancer 139:1546–1556. https://doi.org/10.1002/ijc.30196

Article  CAS  PubMed  Google Scholar 

Gonin-Laurent N, Gibaud A, Huygue M, Lefèvre SH, Le Bras M, Chauveinc L, Sastre-Garau X, Doz F, Lumbroso L, Chevillard S, Malfoy B (2006) Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27:1266–1272. https://doi.org/10.1093/carcin/bgi356

Article  CAS  PubMed  Google Scholar 

Mruthyunjayappa S, Zhang K, Zhang L, Eltoum IA, Siegal GP, Wei S (2019) Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Hum Pathol 92:1–9. https://doi.org/10.1016/j.humpath.2019.07.008

Article  PubMed  Google Scholar 

Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, Wang L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 23:6113–6119. https://doi.org/10.1158/1078-0432.CCR-16-3227

Article  CAS  PubMed  Google Scholar 

Bakhuizen JJ, Hogervorst FB, Velthuizen ME, Ruijs MW, van Engelen K, van Os TA, Gille JJ, Collée M, van den Ouweland AM, van Asperen CJ, Kets CM, Mensenkamp AR, Leter EM, Blok MJ, de Jong MM, Ausems MG (2019) TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort. Fam Cancer 18:273–280. https://doi.org/10.1007/s10689-018-00118-0

Article